Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunobridging study of an E. coli–produced 9-valent HPV vaccine in healthy participants aged 9-17 years
CTR20212272Phase 3Active
- Sponsor
- Xiamen Wantai Canghai Biotechnology Co., Ltd.
- Start
- Sep 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, anogenital warts and Cervical Cancer (CC) (3 arms), sponsored by Xiamen Wantai Canghai Biotechnology Co., Ltd. Primary endpoint: Seroconversion rate and antibody levels at month 7 in the per-protocol three-dose group. Started Sep 2021; status: active.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionanogenital wartsCervical Cancer (CC)
Beyond the preview
Go deeper on CTR20212272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212272.